@article{d6ece4de75d14b26a9c6cd13849ad35e,
title = "Phase 1b trial of pembrolizumab monotherapy for relapsed/refractory multiple myeloma: KEYNOTE-013",
keywords = "PD-1 (PDCD1), multiple myeloma, pembrolizumab",
author = "Vincent Ribrag and Avigan, \{David E.\} and Green, \{Damian J.\} and Trisha Wise-Draper and Posada, \{Juan G.\} and Ravi Vij and Ying Zhu and Farooqui, \{Mohammed Z.H.\} and Patricia Marinello and Siegel, \{David S.\}",
note = "Funding Information: The authors thank the patients and their families and all investigators and site personnel. The authors also thank Jen-nifer Park, Karen Giallella, Brook Burton, Seth Thompson, Kathleen Fox (employees of Merck Sharp \& Dohme Corp., a subsidiary of Merck \& Co., Inc., Kenilworth, NJ, USA) and Roger Dansey (former employee of Merck Sharp \& Dohme Corp., a subsidiary of Merck \& Co., Inc., Kenilworth, NJ, USA) for their contributions to the development of the manuscript. Medical writing and/or editorial assistance was provided by Jacqueline Kolston, PhD, Doyel Mitra, PhD and Matthew Grzywacz, PhD, of the ApotheCom pembrolizumab team (Yardley, PA, USA). This assistance was funded by Merck Sharp \& Dohme Corp., a subsidiary of Merck \& Co., Inc., Kenilworth, NJ, USA. Funding for this research was provided by Merck Sharp \& Dohme Corp., a subsidiary of Merck \& Co., Inc., Kenilworth, NJ, USA.",
year = "2019",
month = aug,
doi = "10.1111/bjh.15888",
language = "English",
volume = "186",
pages = "e41--e44",
journal = "British Journal of Haematology",
issn = "0007-1048",
number = "3",
}